Skip to main content
SpringerLink
Log in
Book cover

Ergot Alkaloids and Related Compounds pp 1–28Cite as

Introduction to the Pharmacology of Ergot Alkaloids and Related Compounds as a Basis of Their Therapeutic Application

  • Chapter

Abstract

This chapter, rather unorthodox for a volume of the Handbook of Experimental Pharmacology, is not intended as a summary of the wealth of information accumulated in this book. It is an attempt at a compact synopsis to help those teaching pharmacology or writing a textbook of pharmacology not to overlook the essential chemical and biological basis of the therapeutically most important compounds and those of their activities which are believed to be relevant for their therapeutic effects.

“Truth is rarely pure and never simple”

Oscar Wilde

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Aellig, W.H., Berde, B.: Studies of the effect of natural and synthetic polypeptide type ergot compounds on a peripheral vascular bed. Brit. J. Pharmacol. 36, 561–570 (1969)

    CAS  Google Scholar 

  • Ahlquist, R.P.: A study of the adrenotropic receptors. Amer. J. Physiol. 153, 586–600 (1948)

    PubMed  CAS  Google Scholar 

  • Altman, S.G., Waltman, R., Lubin, S., Reynolds, S.R.M.: Oxytocic and toxic actions of dihydroergotamine-45. Amer. J. Obstet. Gynec. 64, 101–109 (1952)

    PubMed  CAS  Google Scholar 

  • Benzi, G., De Bernardi, M., Manzo, L., Ferrara, A., Panceri, P., Arrigoni, E., Berte, F.: Effect of lysergide and nimergoline on glucose metabolism investigated on the dog brain isolated in situ. J. pharm. Sci. 61, 348–352 (1972)

    PubMed  CAS  Google Scholar 

  • Berde, B.: Recent progress in the elucidation of the mechanism of action of ergot compounds used in migraine therapy. Med. J. Aust. Spec. Suppl. 2, 15–26 (1972)

    Google Scholar 

  • Berde, B.: Human plasma levels of anti-migraine drugs contrasted with their active concentrations in isolated organ systems. The Bergen Migraine Symposium, Bergen, 4–6 June, 1975

    Google Scholar 

  • Berde, B., Cerletti, A., Dengler, H.J., Zoglio, M.A.: Studies of the interaction between ergot alkaloids and xanthine derivatives. In: Background to Migraine. Cochrane, A.L. (ed.), pp. 80–102. London: William Heinemann Medical Books 1970

    Google Scholar 

  • Berde, B., Rothlin, E.: Über die Uteruswirkung hydrierter Mutterkornalkaloide an Kaninchen und Katzen vor, während und nach der Geburt. Helv. physiol. pharmacol. Acta 11, 274–282 (1953)

    PubMed  CAS  Google Scholar 

  • Berde, B., Saameli, K.: Evaluation of substances acting on the uterus. In: Methods in Drug Evaluation. Mantegazza, P., Piccinini, F. (eds.), pp. 481–514. Amsterdam: North Holland Publ. 1966

    Google Scholar 

  • Besser, G.M., Parke, L., Edwards, C.R.W., Forsyth, I.A., McNeilly, A.S.: Galactorrhoea: successful treatment with reduction of plasma prolactin levels by brom-ergocryptine. Brit. med. J. 3, 669–672 (1972)

    PubMed  CAS  Google Scholar 

  • Billeter, E., Fluckiger, E.: Evidence for a luteolytic function of prolactin in the intact cyclic rat using 2-Br-α-Ergokryptine (CB 154). Experientia (Basel) 27, 464–465 (1971)

    CAS  Google Scholar 

  • Boismare, F., Lorenzo, J.: Study of the protection afforded by nicergoline against the effects of cerebral ischemia in the cat. Arzneimittel-Forsch. 25, 410–413 (1975)

    CAS  Google Scholar 

  • Bradley, P.B., Briggs, I.: Ergot alkaloids and related substances. In: Neuropoisons—Their Pathophysiological Actions. Poisons of Plant Origin. Simpson, L.L., Curtis, D.R. (eds.), Vol. II, pp. 249–296. New York-London: Plenum Press 1974

    Google Scholar 

  • Brody, T.M., Diamond, J.: Blockade of the biochemical correlates of contraction and relaxation in uterine and intestinal smooth muscle. Ann. N.Y. Acad. Sci. 139, 772–780 (1967)

    PubMed  CAS  Google Scholar 

  • Brown, G.L., Dale, Sir Henry: The pharmacology of ergometrine. Proc. roy. Soc. B. 118, 446–477 (1935)

    CAS  Google Scholar 

  • Brugger, J.: Die isolierte Samenblase des Meerschweinchens als biologisches Testobjekt zur quantitativen Differenzierung der sympathikolytischen Wirkung der genuinen Mutterkornalkaloide und ihrer Dihydroderivate. Helv. physiol. pharmacol. Acta 3, 117–134 (1945)

    CAS  Google Scholar 

  • Calne, D.B., Kartzinel, R., Shoulson, I.: An ergot derivative in the treatment of Parkinson’s disease. Postgrad. med. J. 52 (Suppl. 1), 81–82 (1976)

    PubMed  Google Scholar 

  • Carpi, A., Virno, M.: The action of ergotamine on the intracranial venous pressure and on the cerebral venous outflow of the dog. Brit. J. Pharmacol. 12, 232–239 (1957)

    PubMed  CAS  Google Scholar 

  • Cerletti, A., Berde, B., Doepfner, W., Emmenegger, H., Konzett, H., Schalch, W.R., Taeschler, M., Weidmann, H.: Deseril® (methysergide, UML-491), a specific serotonin antagonist. Sci. Exhibit 6th Internat. Congr. Int. Medicine, Basle, 24–27 August, 1960

    Google Scholar 

  • Cerletti, A., Emmenegger, H., Enz, A., Iwangoff, P., Meier-Ruge, W., Musil, J.: Effects of ergot DH-alkaloids on the metabolism and function of the brain. An approach based on studies with DH-ergonine. In: Central Nervous System — Studies on Metabolic Regulation and Function. Genazzani, E., Herken, H. (eds.), pp. 201–212. Berlin-Heidelberg-New York: Springer 1973

    Google Scholar 

  • Chu, D., Owen, D.A.A., Stürmer, E.: Effects of ergotamine and dihydroergotamine on the resistance and capacitance vessels of skin and skeletal muscle in the cat. Postgrad. med. J. 52 (Suppl. 1), 32–36 (1976)

    CAS  Google Scholar 

  • Cleary, R.E., Crabtree, R., Lemberger, L.: The effect of lergotrile on galactorrhea and gonadotropin secretion. J. clin. Endocr. 40, 830–833 (1975)

    PubMed  CAS  Google Scholar 

  • Clemens, J.A., Smalstig, E.B., Shaar, C.J.: Inhibition of prolactin secretion by lergotrile mesylate: mechanism of action. Acta endocr. (Kbh.) 79, 230–237 (1975)

    CAS  Google Scholar 

  • Corrodi, H., Fuxe, K., Hökfelt, T., Lidbrink, P., Ungerstedt, U.: Effect of ergot drugs on central catecholamine neurons: evidence for a stimulation of central dopamine neurons. Letters to the Editor. J. Pharm. Pharmacol. 25, 409–412 (1973)

    CAS  Google Scholar 

  • Del Pozo, E., Flückiger, E.: Prolactin inhibition: experimental and clinical studies. In: Human Prolactin. Pasteels, J.L., Robyn, C. (eds.), pp. 291–301. Amsterdam: Excerpta Medica 1973

    Google Scholar 

  • Del Pozo, E., Goldstein, M., Friesen, H., Brun Del Re, R., Eppenberger, U.: Lack of action of prolactin suppression on the regulation of the human menstrual cycle. Amer. J. Obstet. Gynec. 123, 719–723 (1975)

    PubMed  Google Scholar 

  • Del Pozo, E., Brun del Re, R., Varga, L., Friesen, H.: The inhibition of prolactin secretion in man by CB-154 (2-Br-α-ergocryptine). J. clin. Endocr. 35, 768–771 (1972)

    PubMed  Google Scholar 

  • Depoortere, H, Loew, D.M., Vigouret, J.M.: Neuropharmacological studies on Hydergine®. Triangle 14, 73–79 (1975)

    PubMed  CAS  Google Scholar 

  • Dühler, K.D., Wuttke, W.: Total blockade of phasic pituitary prolactin release in rats: effect on serum LH and progesterone during the estrous cycle and pregnancy. Endocrinology 94, 1595–1600 (1974)

    Google Scholar 

  • Dudley, H.W., Moir, Ch.: The substance responsible for the traditional clinical effect of ergot. Brit. med. J. I, 520–523 (1935)

    CAS  Google Scholar 

  • Embrey, M.P., Garrett, W.J.: A study of the effects of dihydroergotamine on the intact human uterus. J. Obstet. Gynaec. Brit. Emp. 62, 150–154 (1955)

    PubMed  CAS  Google Scholar 

  • Emmenegger, H., Meier-Ruge, W.: The actions of Hydergine® on the brain. A histochemical, circulatory and neurophysiological study. Pharmacology 1, 65–78 (1968)

    PubMed  CAS  Google Scholar 

  • Euler, U.S. v., Hesser, C.M.: Beobachtungen über Hemmungen der Sinusdruckreflexe durch Ergotamin, Dihydroergotamin und Hyperventilation. Schweiz. med. Wschr. 77, 20–21 (1947)

    Google Scholar 

  • Euler, U.S. v., Schmiterlöw, C.G.: The action of ergotamine on the chemical and mechanical reflexes from the carotid sinus region. Acta physiol. pharmacol. scand. 8, 122–133 (1944)

    Google Scholar 

  • Fanchamps, A.: Migraine and related types of headache — Pathogenesis and Therapy. S. Afr. Practit. 3, 33–40 (1958)

    Google Scholar 

  • Fanchamps, A., Doepfner, W., Weidmann, H., Cerletti, A.: Pharmakologische Charakterisierung von Deseril®, einem Serotonin-Antagonisten. Schweiz. med. Wschr. 90, 1040–1046 (1960)

    PubMed  CAS  Google Scholar 

  • Flückiger, E.: Drugs and the control of prolactin secretion. In: Prolactin and Carcinogenesis. Proc. 4th Tenovus Workshop. Boyns, A.R., Griffiths, K. (eds.), pp. 162–180. Cardiff: Alpha Omega Alpha 1972

    Google Scholar 

  • Flückiger, E.: Pharmacological characterization of CB 154 (bromocriptin). Triangle 14, 153–157 (1975)

    Google Scholar 

  • Flückiger, E., Billeter, E., Wagner, H.R.: Inhibition of lactation in rabbits by 2-Br-α-ergokryptine-mesilate (CB 154). Arzneimittel-Forsch. 26, 51–53 (1976a)

    Google Scholar 

  • Flückiger, E., Doepfner, W., Markó, M., Niederer, W.: Effects of ergot alkaloids on the hypothalamic-pituitary axis. Postgrad. med. J. 52 (Suppl. 1), 57–61 (1976b)

    PubMed  Google Scholar 

  • Flückiger, E., Lutterbeck, P.M., Wagner, H.R., Billeter, E.: Antagonism of 2-Br-α-ergokryptine-methanesulfonate (CB 154) to certain endocrine actions of centrally active drugs. Experientia (Basel) 28, 924–925 (1972)

    Google Scholar 

  • Flückiger, E., Wagner, H.R.: 2-Br-α-Ergokryptin: Beeinflussung von Fertilität und Laktation bei der Ratte. Experientia (Basel) 24, 1130–1131 (1968)

    Google Scholar 

  • Fozard, J.R.: The animal pharmacology of drugs in the treatment of migraine. In: Migraine and Related Headaches. Saxena, P.R. (ed.), pp. 93–118. Rotterdam: Erasmus University 1975a

    Google Scholar 

  • Fozard, J.R.: The animal pharmacology of drugs used in the treatment of migraine. J. Pharm. Pharmacol. 27, 297–321 (1975b)

    PubMed  CAS  Google Scholar 

  • Frantz, A.G., Kleinberg, D.L., Noel, G.L.: Studies on prolactin in man. Recent Progr. Hormone Res. 28, 527–590 (1972)

    PubMed  CAS  Google Scholar 

  • Friesen, H., Hwang, P., Guyda, H., Tolis, G., Tyson, J., Myers, R.: A radioimmunoassay for human prolactin. In: Prolactin and Carcinogenesis. Proc. 4th Tenovus Workshop. Boyns, A.R., Griffiths, K. (eds.), pp. 64–80. Cardiff: Alpha Omega Alpha 1972

    Google Scholar 

  • Gaddum, J.H., Hameed, K.A.: Drugs which antagonise 5-hydroxy-tryptamine. Brit. J. Pharmacol. 9, 240–248 (1954)

    PubMed  CAS  Google Scholar 

  • Gygax, P., Meier-Ruge, W., Schulz, U., Enz, A.: Experimental studies on the action of metabolic and vasoactive substances in the oligemically disturbed brain. Arzneimittel-Forsch. 26, 1245–1246 (1976)

    CAS  Google Scholar 

  • Hart, I.C.: Effect of 2-bromo-α-ergocryptine on milk yield and the level of prolactin and growth hormone in the blood of the goat at milking. J. Endocr. 57, 179–180 (1973)

    PubMed  CAS  Google Scholar 

  • Hart, I.C.: The relationship between lactation and the release of prolactin and growth hormone in the goat. J. Reprod. Fertil. 39, 485–499 (1974)

    PubMed  CAS  Google Scholar 

  • Hill-Samli, M., MacLeod, R.M.: Thyrotropin-releasing hormone blockade of the ergocryptine and apomorphine inhibition of prolactin release in vitro. Proc. Soc. exp. Biol. (N.Y.) 149, 511–514 (1975)

    CAS  Google Scholar 

  • Hökfelt, T., Fuxe, K.: On the morphology and the neuroendocrine role of the hypothalamic catecholamine neurons. In: Brain-Endocrine Interaction. Knigge, K.M., Scott, D.E., Weindl, A. (eds.), pp. 181–223. Basel: Karger 1972

    Google Scholar 

  • Hool-Zulauf, B., Stürmer, E.: Oxytocic activity of two dihydro-ergot peptide alkaloids on the rabbit uterus in situ. Naunyn-Schmiedeberg’s Arch. Pharmacol. 293, (Suppl.) R 35 (1976)

    Google Scholar 

  • Hool-Zulauf, B., Stürmer, E.: Oxytocic activity of two dihydrogenated ergot peptide alkaloids on the rabbit uterus in situ. Arzneimittel-Forsch. 27, 2323–2325 (1977)

    CAS  Google Scholar 

  • Iwangoff, P., Enz, A., Chappuis, A.: Inhibition of cAMP-phosphodiesterase of different cat organs by DH-ergotoxine in the micromolar substrate range. Int. Res. Commun. System med. Sci. 3, 403 (1975)

    CAS  Google Scholar 

  • Johnson, A.M., Loew, D.M., Vigouret, J.M.: Stimulant properties of bromocriptine on central dopamine receptors in comparison to apomorphine, (+)-amphetamine and L-dopa. Brit. J. Pharmacol. 56, 59–68 (1976)

    CAS  Google Scholar 

  • Johnson, A.M., Vigouret, J.M., Loew, D.M.: Central dopaminergic actions of ergotoxine alkaloids and some derivatives. Experientia (Basel) 29, 763 (1973)

    Google Scholar 

  • Karg, H., Schams, D., Reinhardt, V.: Effects of 2-Br-α-ergocryptine on plasma prolactin level and milk yield in cows. Experientia (Basel) 28, 574–576 (1972)

    CAS  Google Scholar 

  • Kharasch, M.S., King, H., Stoll, A., Thompson, M.R.: The new ergot alkaloid. Science 83, 206–207 (1936)

    PubMed  CAS  Google Scholar 

  • Kirchhof, A.C., Racely, C.A., Wilson, W., David, N.A.: An ergonovine-like oxytocic synthesized from lysergic acid. West. J. Surg. 52, 197–208 (1944)

    CAS  Google Scholar 

  • Konzett, H.: Specific antagonism of dibenamine to ergometrine. Ciba Foundation Symposium on Adrenergic Mechanisms. Wolstenholme, G.E.W., O’Connor, M. (eds.), pp. 463–465. London: Churchill 1960

    Google Scholar 

  • Lance, J.W.: The Mechanism and Management of Headache. London: Butterworths 1969

    Google Scholar 

  • Lance, J.W.: The pathophysiology and treatment of migraine. N.Z. med. J. 79, 954–960 (1974)

    PubMed  CAS  Google Scholar 

  • Lieberman, A., Miyamoto, T., Battista, A.F., Goldstein, M.: Studies on the antiparkinsonian efficacy of lergotrile. Neurology (Minneap.) 25, 459–462 (1975)

    CAS  Google Scholar 

  • Loew, D.M., Vigouret, J.M., Jaton, A.L.: Neuropharmacological investigations with two ergot alkaloids, Hydergine and bromocriptine. Postgrad. med. J. 52 (Suppl. 1), 40–46 (1976)

    PubMed  CAS  Google Scholar 

  • Lutterbeck, P.M., Pryor, J.S., Varga, L., Wenner, R.: Treatment of non-puerperal galactorrhea with an ergot alkaloid. Brit. med. J. 3, 228–229 (1971)

    PubMed  CAS  Google Scholar 

  • MacLeod, R.M., Lehmeyer, J.E.: Studies on the mechanism of the dopamine-mediated inhibition of prolactin secretion. Endocrinology 94, 1077–1085 (1974)

    PubMed  CAS  Google Scholar 

  • Markó, M., Flückiger, E.: Inhibition of spontaneous and induced ovulation in rats by nonsteroidal agents. Experientia (Basel) 30, 1174–1176 (1974)

    Google Scholar 

  • Markstein, R., Wagner, H.: The effect of dihydroergotoxin, phentolamine and pindolol on catecholamine-stimulated adenylcyclase in rat cerebral cortex. FEBS Lett. 55, 255–257 (1975)

    Google Scholar 

  • Markstein, R., Wagner, H.: Effect of dihydroergotoxine on cyclic AMP generating systems in rat cerebral cortex slices. Gerontology (1978) (in press)

    Google Scholar 

  • Matejcek, M., Devos, J.E.: Selected methods of quantitative EEG analysis and their applications in psychotropic drug research. In: Quantitative Analytic Studies in Epilepsy. Kellaway, P., Petersen, I. (eds.), pp. 183–205. New York: Raven Press 1976

    Google Scholar 

  • Mayer, P., Schütze, E.: Effect of 2-Br-α-ergokryptine (CB 154) on lactation in the bitch. Experientia (Basel) 29, 484–485 (1973)

    CAS  Google Scholar 

  • Meier, J., Schreier, E.: Human plasma levels of some anti-migraine drugs. Headache 16, 96–104 (1976)

    PubMed  CAS  Google Scholar 

  • Meier-Ruge, W., Enz, A., Gygax, P., Hunziker, O., Iwangoff, P., Reichlmeier, K.: Experimental pathology in basic research of the aging brain. In: Aging. Gershon, S., Raskin, A. (eds.), Vol. II, pp. 55–126. New York: Raven Press 1975

    Google Scholar 

  • Mellander, S., Nordenfelt, I.: Comparative effects of dihydroergotamine and noradrenaline on resistance, exchange and capacitance functions in the peripheral circulation. Clin. Sci. 39, 183–201 (1970)

    PubMed  CAS  Google Scholar 

  • Miller, J.W.: Adrenergic receptors in the myometrium. Ann. N.Y. Acad. Sci. 139, 788–798 (1967)

    PubMed  CAS  Google Scholar 

  • Miller, M.D., Marshall, J.M.: Uterine response to nerve stimulation; relation to hormonal status and catecholamines. Amer. J. Physiol. 209, 859–865 (1965)

    PubMed  CAS  Google Scholar 

  • Moir, C.: The action of ergot preparations on the puerperal uterus. Brit. med. J. I, 1119–1122 (1932)

    Google Scholar 

  • Müller-Schweinitzer, E.: Responsiveness of isolated canine cerebral and peripheral arteries to ergotamine. Naunyn-Schmiedeberg’s Arch. Pharmacol. 292, 113–118 (1976)

    Google Scholar 

  • Müller-Schweinitzer, E., Stürmer, E.: Investigations on the mode of action of ergotamine in the isolated femoral vein of the dog. Brit. J. Pharmacol. 51, 441–446 (1974)

    Google Scholar 

  • Nagasawa, H., Yanai, R., Flückiger, E.: Counteraction by 2-Br-α-ergocryptine of pituitary prolactin release promoted by dibutyryladenosine 3′,5′,-monophosphate in rats. In: Human Prolactin. Pasteels, J.L., Robyn, C. (eds.), pp. 313–315. Amsterdam: Excerpta Medica 1973

    Google Scholar 

  • Niswender, G.D.: Influence of 2-Br-α-ergocryptine on serum levels of prolactin and the estrous cycle in sheep. Endocrinology 94, 612–615 (1974)

    PubMed  CAS  Google Scholar 

  • Nordenfelt, I., Mellander, S.: Central haemodynamic effects of dihydroergotamine in patients with orthostatic hypotension. Acta med. scand. 191, 115–120 (1972)

    PubMed  CAS  Google Scholar 

  • Ostfeld, A.M., Chapman, L.F., Goodell, H., Wolff, H.G.: Studies in headache. Summary of evidence concerning a noxious agent active locally during migraine headache. Psychosom. Med. 19, 199–208 (1957)

    PubMed  CAS  Google Scholar 

  • Owen, D.A.A., Herd, J.K., Kalberer, F., Pacha, W., Salzmann, R.: The influence of ergotamine and methysergide on the storage of biogenic amines. In: Proceedings of the International Headache Symposium, Elsinore, 16–18 May, 1971. Dalessio, D.J., Dalsgaard-Nielsen, T., Diamond, S. (eds.), pp. 153–161. Basle: Sandoz 1971

    Google Scholar 

  • Owen, D.A.A., Stürmer, E.: The effects of ergotamine and dihydroergotamine on skin and skeletal muscle vasculature. Experientia (Basel) 28, 743 (1972)

    Google Scholar 

  • Pacha, W., Salzmann, R.: Inhibition of the re-uptake of neuronally liberated noradrenaline and alpha-receptor blocking action of some ergot alkaloids. Brit. J. Pharmacol. 38, 439–440 (1970)

    Google Scholar 

  • Pasteels, J.L., Danguy, A., Frérotte, M., Ectors, F.: Inhibition de la sécrétion de prolactine par l’ergocornine et la 2-Br-α-ergocryptine: action directe sur l’hypophyse en culture. Ann. Endocr. (Paris) 32, 188–192 (1971)

    CAS  Google Scholar 

  • Pichler, E., Lazarini, W., Filippi, R.: Über schraubenförmige Struktur von Arterien. II. Mitt.: Pharmakologische Strukturanalyse von Hirnarterien. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmac. 219, 420–439 (1953)

    CAS  Google Scholar 

  • Rothlin, E.: Recherches expérimentales sur l’ergotamine, alcaloide spécifique de l’ergot de seigle. Arch. int. Pharmacodyn. 27, 459–479 (1923)

    CAS  Google Scholar 

  • Rothlin, E.: Beitrag zur differenzierenden Analyse der Mutterkornalkaloide. Schweiz. med. Wschr. 33, 971–975 (1938)

    Google Scholar 

  • Rothlin, E.: The pharmacology of the natural and dihydrogenated alkaloids of ergot. Bull. schweiz. Akad. med. Wiss. 2, 249–272 (1947)

    PubMed  CAS  Google Scholar 

  • Rothlin, E., Berde, B.: Über die Wirkung hydrierter Mutterkornalkaloide auf isolierte Muskelstreifen des menschlichen Uterus nahe am Termin, am Termin und wahrend der Geburt. Helv. physiol. pharmacol. Acta 12, 191–205 (1954)

    PubMed  CAS  Google Scholar 

  • Rothlin, E., Bircher, R.: Allergy, the autonomic nervous system and ergot alkaloids. Progr. Allergy 3, 434–484 (1952)

    Google Scholar 

  • Rothlin, E., Cerletti, A.: Untersuchungen über die Kreislaufwirkung des Ergotamin. Helv. physiol. pharmacol. Acta 7, 333–370 (1949)

    PubMed  CAS  Google Scholar 

  • Roubicek, J., Geiger, Ch., Abt, K.: An ergot alkaloid preparation (Hydergine) in geriatric therapy. J. Amer. Geriat. Soc. 20, 222–229 (1972)

    PubMed  CAS  Google Scholar 

  • Roubicek, J., Matejcek, M., Montague, S.: The EEG in old age. Electroenceph. clin. Neurophysiol. 34, 718 (1973)

    Google Scholar 

  • Saxena, P.R.: The effects of antimigraine drugs on the vascular responses by 5-hydroxytryptamine and related biogenic substances on the external carotid artery bed of dogs: Possible pharmacological implications to their antimigraine action. Headache 12, 44–54 (1972)

    PubMed  CAS  Google Scholar 

  • Saxena, P.R.: Selective vasoconstriction in carotid vascular bed by methysergide: Possible relevance to its antimigraine effect. Europ. J. Pharmacol. 27, 99–105 (1974)

    CAS  Google Scholar 

  • Saxena, P.R., Vlaam-Schluter, G.M. de: Role of some biogenic substances in migraine and relevant mechanism in antimigraine action of ergotamine — studies in an experimental model for migraine. Headache 13, 142–163 (1974)

    PubMed  CAS  Google Scholar 

  • Schams, D., Reinhardt, V., Karg, H.: Effects of 2-Br-α-ergokryptine on plasma prolactin level during parturition and onset of lactation in cows. Experientia (Basel) 28, 697–699 (1972)

    CAS  Google Scholar 

  • Schmidt, R., Fanchamps, A.: Effect of caffeine on intestinal absorption of ergotamine in man. Europ. J. clin. Pharmacol. 7, 213–216 (1974)

    CAS  Google Scholar 

  • Shelesnyak, M.C.: Ergotoxine inhibition of deciduoma formation and its reversal by progesterone. Amer. J. Physiol. 179, 301–304 (1954)

    PubMed  CAS  Google Scholar 

  • Shelesnyak, M.C.: Maintenance of gestation in ergotoxine-treated pregnant rats by exogenous prolactin. Acta endocr. (Kbh.) 27, 99–109 (1958)

    CAS  Google Scholar 

  • Sicuteri, F.: Prophylactic and therapeutic properties of 1-methyl-lysergic acid butanolamide in migraine. Int. Arch. Allergy 15, 300–307 (1959)

    PubMed  CAS  Google Scholar 

  • Sinha, Y.N., Salocks, C.B., Lewis, U.J., Vanderlaan, W.P.: Influence of nursing on the release of prolactin and GH in mice with high and low incidence of mammary tumors. Endocrinology 95, 947–954 (1974)

    PubMed  CAS  Google Scholar 

  • Sinha, Y.N., Selby, F.W., Vanderlaan, W.P.: Effects of ergot drugs on prolactin and growth hormone secretion, and on mammary nucleic acid content in C3H/Bi mice. J. nat. Cancer Inst. 52, 189–191 (1974)

    PubMed  CAS  Google Scholar 

  • Smith, V.G., Beck, T.W., Convey, E.M., Tucker, H.A.: Bovine serum prolactin, growth hormone, Cortisol and milk yield after ergocryptine. Neuroendocrinology 15, 172–181 (1974)

    PubMed  CAS  Google Scholar 

  • Stadler, P.A., Stürmer, E.: Comparative studies on the pharmacological properties of stereoisomers of ergotamine and dihydroergotamine. Naunyn-Schmiedeberg’s Arch. Pharmac. 266, 457 (1970)

    CAS  Google Scholar 

  • Stadler, P.A., Stürmer, E.: Synthese und biologische Aktivitäten einiger Stereoisomeren von Ergotamin und Dihydro-ergotamin. Chimia 26, 321 (1972)

    Google Scholar 

  • Stähelin, H., Burckhardt-Vischer, B., Flückiger, E.: Rat mammary cancer inhibition by a prolactin suppressor, 2-bromo-α-ergokryptine (CB 154). Experientia (Basel) 27, 915–916 (1971)

    Google Scholar 

  • Stoll, A.: Ergot—a treasure house for drugs. Pharm. J. 194, 605–613 (1965)

    Google Scholar 

  • Stoll, A., Hofmann, A.: Partialsynthese von Alkaloiden vom Typus des Ergobasins. 6. Mitt. über Mutterkornalkaloide. Helv. chim. Acta 26 (Fasc. 3), 944–965 (1943)

    CAS  Google Scholar 

  • Stürmer, E., Flückiger, E.: In vivo smooth muscle stimulant activity of 2-bromo-α-ergokryptine mesylate (CB 154) as compared with that of ergotamine. Int. Res. Commun. System med. Sci. 2, 1591 (1974)

    Google Scholar 

  • Suchowsky, G.K., Pegrassi, L.: Action of nicergoline on electroencephalographic recovery after cat brain ischemia. Naunyn-Schmiedeberg’s Arch. Pharmacol. 284, 311–318 (1974)

    CAS  Google Scholar 

  • Takahara, J., Arimura, A., Schally, A.V.: Suppression of prolactin release by a purified porcine PIF preparation and catecholamines infused into a rat hypophysial portal vessel. Endocrinology 95, 462–465 (1974)

    PubMed  CAS  Google Scholar 

  • Tashjian, A.H., Hoyt, R.F.: Transient control on organ specific functions in pituitary cells in culture. In: Molecular Genetics and Development Biology. Sussman, M. (ed.), pp. 353–387. New Jersey: Englewood Cliffs 1972

    Google Scholar 

  • Thorner, M.O., Besser, G.M.: Successful treatment of acromegaly with bromocriptine. Postgrad. med. J. 52 (Suppl. 1), 71–74 (1976)

    PubMed  Google Scholar 

  • Toda, N., Fujita, Y.: Responsiveness of isolated cerebral and peripheral arteries to serotonin, norepinephrine and transmural electrical stimulation. Circulat. Res. 33, 98–104 (1973)

    PubMed  CAS  Google Scholar 

  • Weidmann, H., Taeschler, M.: Influence des substances antimigraineuses sur les effets des catécholamines, de la sérotonine et de la stimulation des nerfs sympathiques. Discussion du mode d’action des antimigraineux. In: Symposium International sur les Céphalées Vasculaires, St. Germain-en-Laye, 15–16 octobre, 1966, pp. 33–40

    Google Scholar 

  • Wolff, H.G: Pain mechanisms and headache. Triangle 2, 53–64 (1955)

    Google Scholar 

  • Wolff, H.G.: Headache and Other Head Pain. London-New York: Oxford U. Pr. 1963

    Google Scholar 

  • Yanai, R., Nagasawa, H.: Effects of ergocornine and 2-Br-α-ergokryptin (CB-154) on the formation of mammary hyperplastic alveolar nodules and the pituitary prolactin levels in mice. Experientia (Basel) 26, 649–650 (1970)

    CAS  Google Scholar 

Download references

Authors
  1. B. Berde
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. Stürmer
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Forschung und Entwicklung, Pharmazeutisches Departement, Sandoz AG, 4002, Basel, Schweiz

    B. Berde

  2. University College London, London WC1, Great Britain

    H. O. Schild (Emeritus Professor of Pharmacology in the University of London) (Emeritus Professor of Pharmacology in the University of London)

Rights and permissions

Reprints and permissions

Copyright information

© 1978 Springer-Verlag Berlin · Heidelberg

About this chapter

Cite this chapter

Berde, B., Stürmer, E. (1978). Introduction to the Pharmacology of Ergot Alkaloids and Related Compounds as a Basis of Their Therapeutic Application. In: Berde, B., Schild, H.O. (eds) Ergot Alkaloids and Related Compounds. Handbook of Experimental Pharmacology / Handbuch der experimentellen Pharmakologie, vol 49. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-66775-6_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-66775-6_1

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-66777-0

  • Online ISBN: 978-3-642-66775-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation